The role of prognostic and predictive markers in treatment of non-small cell lung cancer

According to current guidelines immunotherapy can be used in treatment of almost all patients with non-small cell lung cancer (NSCLC) except those with activating mutations. At the same time a lot of different drugs combinations are approved in this setting and differences between them are not so obvious, which makes the decision making process quite difficult. Using the example of other tumors, such as kidney cancer or prostate cancer there are some preconditions for treatment tactics planning based on prognostic groups selection. In this article we describe known and
investigated prognostic and predictive factors that can be useful in this context.